Krebs Biochemicals & Industries Limited (KBIL) is an India-based company. Founded in 1991 with the main objective of establishing commercially viable biotech processes for application in medicine, agriculture, and industry, Krebs has been a pioneer in fermentation technology in India. In 1992, the company made its initial public offering and got listed on major stock exchanges such as the Hyderabad Stock Exchange Limited and the Bombay Stock Exchange Limited. It is currently manufacturing androstenedione, lovastatin, and simvastatin. The products that are currently in either pilot or research and development stages are amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine.